IE
DMRA

Israel Englander’s Damora Therapeutics DMRA Stock Holding History

Israel Englander’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-471,646
Closed -$12.2M – 6067
2026
Q1 		$12.2M Buy
+471,646
New +$12.1M 0.01% 1979
2024
Q2 		– Sell
-560
Closed -$10.9K – 6119
2024
Q1 		$10.9K Buy
+560
New +$9.96K ﹤0.01% 5915
2022
Q4 		– Sell
-752
Closed -$36K – 6726
2022
Q3 		$36K Sell
752
-462
-38% -$23.4K ﹤0.01% 6285
2022
Q2 		$53K Buy
1,214
+59
+5% +$2.71K ﹤0.01% 6180
2022
Q1 		$64K Buy
1,155
+45
+4% +$2.53K ﹤0.01% 6320
2021
Q4 		$84K Sell
1,110
-2,224
-67% -$175K ﹤0.01% 6320
2021
Q3 		$299K Buy
+3,334
New +$356K ﹤0.01% 5819
2021
Q2 		– Sell
-3,314
Closed -$503K – 6722
2021
Q1 		$503K Buy
3,314
+514
+18% +$140K ﹤0.01% 4823
2020
Q4 		$875K Buy
+2,800
New +$1.04M ﹤0.01% 3820

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Israel Englander's DMRA Position: Q2 2026 in Review

Israel Englander sold out of Damora Therapeutics (DMRA) in Q2 2026, closing a stake of 471,646 shares — an estimated $12.2M sold.

Israel Englander first reported a position in DMRA in Q4 2020 and held it in 9 quarters. The position peaked at $12.2M in Q1 2026. 103 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Israel Englander reported no remaining Damora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 471,646 Damora Therapeutics shares in Q2 2026, an estimated $12.2M.
  • Israel Englander first reported a position in Damora Therapeutics in Q4 2020 and held it in 9 quarters.
  • Israel Englander's Damora Therapeutics position peaked at $12.2M in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.